Ivorat

Bemiparin Sodium, the active ingredient in Ivorat, is a low molecular weight heparin presented as a subcutaneous injection for subcutaneous use. It is employed to prevent clot formation and to treat established venous thromboembolism, particularly in patients undergoing surgery, those with deep‑vein thrombosis, and medically ill individuals at risk of thromboembolic events.

GNH USA supplies Ivorat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Bemiparin Sodium is a low molecular weight heparin used to manage venous thromboembolism. - Prevention of venous thromboembolism in surgical patients: reduces risk of postoperative deep‑vein thrombosis and pulmonary embolism. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension or recurrence. - Prevention of thromboembolic events in medically ill patients: lowers incidence of clot formation during acute medical illness or immobilization.

Bemiparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: erythema, pain, or induration at the administration site. - Minor bleeding: bruising, epistaxis, or gum bleeding. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Major hemorrhage: internal bleeding such as gastrointestinal or intracranial hemorrhage. - Thrombocytopenia: significant drop in platelet count, potentially leading to bleeding. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Elevated liver enzymes: abnormal hepatic function tests.

When prescribing Bemiparin Sodium, clinicians should consider several precautionary measures to minimize risk. - Renal impairment: adjust use or monitor closely in patients with reduced kidney function. - Active bleeding: avoid in individuals with ongoing hemorrhage or recent major surgery. - Concomitant anticoagulants: assess bleeding risk when combined with other anticoagulant or antiplatelet agents. - History of heparin‑induced thrombocytopenia: contraindicated in patients with prior HIT. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store at ambient temperature: keep in original container, protect from moisture and light, and do not freeze.

Bemiparin Sodium can interact with other medicines, influencing its anticoagulant effect or bleeding risk.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increases bleeding risk. - Potent antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): synergistic effect on hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance minor bleeding. - Thrombolytic therapy (e.g., alteplase): additive anticoagulant effect. - Certain antibiotics (e.g., quinolones) that affect platelet function: monitor for bleeding. - Herbal supplements (e.g., ginkgo, garlic): potential increase in bleeding tendency.